Interleukin -12 ( IL -12 ) mediates significant antitumor effects in animal models but associated with dose -dependent toxicity in human. To achieve local expression of IL -12 at the tumor site without systemic toxicity, we performed intra -arterial administration of fibroblasts genetically engineered to produce IL -12 protein with or without retrovirus ( CRIP -IL -12 or 3T3 -IL -12 ) in liver metastasis model. Rat breast cancer cells ( MADB -106 ) were injected into the portal vein of syngeneic Fisher rats on day 0, and fibroblasts were injected into the hepatic artery on day 7. On day 21, liver weight and number of liver tumors were examined. As controls, CRIP cells expressing retrovirus carrying lacZ marker gene ( CRIP -lacZ ) or saline ( Hanks balanced salt solution, HBSS ) were injected. Administration of CRIP -IL -12 significantly reduced tumor metastasis in liver measured by number of foci ( CRIP -IL -12: 45.2 36.7, CRIP -lacZ: > 250, HBSS: > 250, P < .05 ) and by liver weight ( CRIP -IL -12: 13.0 2.5 g, CRIP -lacZ: 30.4 8.5 g, HBSS: 26.0 7.6 g, P < .05 ) . 3T3 -IL -12, which produced only IL -12 protein but not IL -12 retrovirus, also had significant antitumor effects equivalent to CRIP -IL -12. Intra -arterial injection of IL -12 ± producing fibroblasts into the liver may be an effective therapy for liver tumors reducing systemic toxicity, and could be developed for clinical application.
S ystemic administration of recombinant interleukin 12 (rIL -12) protein has been shown to induce tumor regression in murine model, with the succeeding induction of antitumor systemic immunity. 1, 2 However, systemic administration of rIL -12 in humans was found to be associated with severe side toxicity at levels far lower than the tolerable therapeutic doses for rodents. 3 In theory, if IL -12 can be expressed at the tumor site by local gene therapy, it should allow high cytokine concentration at the tumor site with substantially lower levels of the cytokine in the circulation. We have demonstrated in previous reports that local expression of IL -12 by transduced tumor cells or fibroblasts induce potent antitumor effects in mice, 4 ± 6 leading to a human clinical trial using fibroblasts genetically engineered to express IL -12. 7 Results of a completed phase I clinical protocol have shown that systemic concentration of IL -12 was undetectable even when treated with fibroblasts expressing 9000 ng /24 hours for each injection ( Tahara et al, manuscript submitted ).
In some of these studies, including clinical trial, intradermal tumor lesions have been treated with intratumoral or peritumoral injection of fibroblasts transduced with IL -12 genes. In theory, liver metastasis can be treated in a similar manner by injecting IL -12 ±producing fibroblasts into the hepatic artery because primary hepatoma and metastatic tumor lesions have blood supply from the hepatic artery. 8 In this report, we have tested the efficacy of this strategy in a rat liver metastasis model. In addition, we also tested the IL-12 retroviral producer cell line as a potentially more efficient IL -12 delivery system than IL-12 ±producing fibroblasts. Because IL -12 retroviral producer cell line ( CRIP -IL-12 ) expresses IL -12 protein as well as IL-12 retrovirus at tumor site, it might transduce proliferating tumor cells and show antitumor effects even superior to that of IL -12 fibroblasts.
MATERIALS AND METHODS

Tumor cell line
MADB106 ( generously provided by W. Chambers, Pittsburgh, PA ) , a Fisher rat breast cancer cell line, was maintained in the Fisher rat with subcutaneous (s.c. ) transplantation. Tumor tissue was harvested from the animal, digested with triple enzyme (0.1% collagenase, 0.002% deoxyribonuclease, and 0.01% hyaluronidase) , cultured in the flask for two passages, and used for animal experiment.
Genetically engineered fibroblasts
'CRIP cell is an amphotropic packaging cell line derived from NIH3T3 cells. 9 'CRIP cells were transfected with the TFG -mIL -12 -Neo 6 proviral plasmid and selected in the medium containing 0.75 mg /mL G418 to obtain a retroviral producer cell line (CRIP -IL -12 ). NIH3T3 cells were transduced with retroviral supernatant harvested from CRIP -IL -12 and selected with 0.75 mg / mL G418 to generate IL -12 ± producing fibroblasts (3T3 -IL -12 ). These cells were cultured in flasks using Dulbecco's modified Eagle's medium containing 10% calf serum supplemented with 0.5% HEPES, 100 U /mL penicillin, and 100 g/mL streptomycin. 
Liver tumor model
MADB106 tumor cells ( 2Â10 5 ) were harvested with trypsin from the flask, washed extensively, resuspended in 1.0 mL Hanks balanced salt solution (HBSS ) , and injected into the superior mesenteric vein of Fisher rats ( F344) using 27 -gauge needles after anesthesia of the animals with inhalation of methoxyflurane (Metofane ) . Seven days posttumor injection, 1Â10 6 'CRIP transfectants, 3T3 transfectants, or HBSS were injected into the hepatic artery via gastroduodenal artery ( GDA ) as a therapy using 30-gauge polyethylene tubing after clumping common hepatic artery under anesthesia, or inoculated s.c. Animals were sacrificed 21 days after tumor injection ( 14 days after therapy ), and their livers harvested to be weighed and examined for tumor number on the liver surface in a blinded fashion. All the animal experiments were performed at least twice and the results of the representative one were shown.
LacZ staining
Two days after CRIP lacZ cell injection, livers were harvested and embedded in ornithine carbamoyltransferase ( OCT ) compound and frozen using liquid nitrogen. Serial frozen sections were stained with H&E and X -gal for lacZ. For lacZ staining, frozen sections were fixed with 0.5% glutaraldehyde, incubated with 1 mg /mL X -gal (Sigma, St. Louis, MO ) solution for 3 hours and examined using light microscope for staining. 10 
Statistical analysis
Statistical differences were determined using the nonparametric, Wilcoxon two -sample test; values of P <.05 ( twotailed) were considered significant.
RESULTS
Antitumor effects with transduced fibroblasts
In livers of control groups following MADB106 injection treated with CRIP -lacZ or HBSS, numerous tumor nodules ( > 250 foci ) fused each other to form big lesions, replacing most of normal liver tissue. Intra -arterial injection of CRIP -IL -12 caused a marked reduction in the number of identifiable liver metastasis and liver weight when compared to those of the animals that received CRIP -lacZ or HBSS ( Figs 1 and 2A ) . The differences in the antitumor effect between intra-arterial administration and s.c. administration of CRIP -IL -12 cells was examined to determine whether the antitumor effects of intra -arterial CRIP -IL -12 injection are IWAZAWA, CHAU, MORI, ET AL: IL-12 GENE THERAPY FOR LIVER TUMOR due to the systemic circulation of IL -12 ( Fig 2B ) . Intraarterial administration of CRIP -IL -12 was associated with significantly lower liver weight when compared with that of s.c. administration, which showed only minor antitumor effects.
The antitumor effects of 3T3 -IL -12, which produced only IL -12 protein, but no IL -12 retrovirus, were compared to those of CRIP -IL -12 to examine the potential differences related to the retroviral production and transduction of tumor cells adjacent to the injected site. 3T3 -IL-12 injection resulted in significant antitumor effect similar to that of CRIP -IL -12 (Fig 2C ) in the experiments in which 5.8Â10 5 3T3 -IL-12 mixed with 4.2Â10 5 3T3 -Neo were used to adjust the total IL -12 expression of 3T3 -IL -12 to that of CRIP -IL -12. The injected 3T3 -IL -12 cells produced 38 ng/ 24 hours of IL-12, which was equal to that of 1Â10 6 CRIP -IL-12 cells. Consistent with the results obtained in the experiments using CRIP -IL -12, intra -arterial injection of 3T3 -IL -12 caused significantly better antitumor effects than s.c. injection of the same cells (Fig 2C) .
LacZ staining
In the examination of H&E -stained liver samples, some small necrotic lesions were observed in the area of the liver, and significant number of inflammatory cells were observed around the eosinophilic necrotic liver cells. A small number of lacZ -positive cells were observed in the necrotic lesion ( Fig 3A\ and\ B ) . However, it is unclear if the lacZ -positive cells were injected producer cells or liver cells transduced in situ.
Cell tracking
CRIP -GFP cells were labeled with PKH -26 fluorescent dye ( Sigma ) for cell tracking (Fig 4A and B ) .
Seventeen days after 2Â10
5 tumor cells injection via portal vein, 3Â10
6 of PKH -26 ±labeled CRIP GFP cells were injected via GDA. Animals were sacrificed 2 days later, and livers were harvested and frozen in OCT compound. Frozen sections were prepared and examined immediately by fluorescent microscopy. Some doublepositive cells ( GFP and PKH -26 ), which should be CRIP -GFP cells, were observed in the liver. However, no cells positive only for GFP were observed. These results indicate that there were no or few cells (hepatocytes, parenchymal cells, or tumor cells ) infected with virus produced by CRIP -GFP cells ( Fig 4C,D ) . No positive cells were observed when CRIP -Zeo cells were injected without PKH -26 labeling.
DISCUSSION
IL -12 is a heterodimetric cytokine originally identified by its ability to induce the maturation of cytolytic lymphocytes or activation of NK cells. IL -12 facilitates the generation of antigen -specific cytolytic T lymphocytes, maintains tumor-infiltrating lymphocytes in culture, and induces the secretion of high levels of IFNfrom both T cells and NK cells in vivo and in vitro. Because IL -12 is secreted exclusively by professional antigen presenting cells (APC, monocytes, and B cells) and IL -12 receptors are expressed selectively on activated T lymphocytes and NK or NK -T cells, it appears that IL -12 is well -suited to drive the expansion and maturation of T, NK, and NK -T cells, the most prevalent antitumor effector cells localized within tumor lesions. 11 ± 19 Previous and current observations, including ours, in murine models suggest that IL -12 is a very promising candidate as a reagent to be used in cancer immunotherapy. In this study, we used intra-arterial injection of IL -12 retroviral producer cells into the hepatic artery for treatment of liver metastasis. Intra -arterial administration should result in high local concentration of the cytokine at the tumor site with lower systemic concentration, reducing systemic toxicity. Because the amount of IL -12 made available at the tumor site is critical for tumor regression, 22 this strategy appears to have greater advantage over systemic administration. In our rat liver metastasis model, the antitumor effects of intra-arterial administration were significantly better than s.c. administration of the same cells. This difference appears to be due to the fact that intra-arterial administration of CRIP -IL -12 cells leads to a high level of IL -12 available at the tumor site. Furthermore, cells injected via GDA appear to be delivered through the blood supply to most of multifocal liver tumor nodules. We performed intraarterial (GDA ) injection rather than portal injection of transfected fibroblasts, because liver tumors have blood supply mainly from the hepatic artery, but not from the portal vein. 8 Because injected retroviral producer cells express both IL -12 protein and retrovirus at the tumor site, the tumor cells also could be transduced to express IL -12. Intratumoral injection of retroviral producer cell lines has been used in both animal studies and clinical studies as a strategy to treat brain tumors using herpes simplex virus thymidine kinase ( HSV-TK ) gene expression. 23 ± 25 To test whether infection of the tumor occurred in vivo, we first examined the transduction efficiency of this strategy using lacZ marker gene. In such study, we found lacZ ( + ) cells in small necrotic lesions in the liver 2 or 4 days after intra -arterial administration of CRIP -lacZ cells. This finding suggests that injected cells caused embolization of small arteries leading to the necrosis of tumor cells or normal hepatocytes. However, this study could not discriminate whether the lacZ ( + ) cells were injected fibroblasts (CRIP -lacZ ) or infected host cells (tumor cells, hepatocytes, or parenchymal cells of the liver ) by retroviral vector. To further examine this question, we performed the cell tracking using CRIP GFP -Zeo cells labeled with PKH -26 fluorescent dye. All of the GFPpositive cells were also positive for red fluorescence ( PKH -26 ). No infected host cells, which should be GFP positive but PKH -26 negative, were found in the liver or even in tumor nodules 2 days after the injection of the cells. Inability to detect transduced tumor cells might be due to the titer of our producer cell line and/ or the route of administration. The poor transduction efficiency, however, is consistent with and appears to be a good explanation for our finding that the antitumor effects of the intra-arterial injection of CRIP -IL -12 cells had no significant advantage over that of 3T3 -IL -12 cells, which produced the same amount of IL -12 protein as CRIP -IL -12 cells. These results indicate that intra -arterial injection of IL -12 expressing fibroblasts can cause significant suppression of tumor progression in liver at the same extent as the IL -12 ±producer cells we used.
Intra -arterial injection of IL -12 ± producing fibroblasts, not retroviral producer cells, into the liver may be a safe and an effective therapy for liver tumors, and could be developed for clinical evaluation.
